Biosimilars: where are we now and the role of pharmacists 

• Does brand prescribing for biosimilars matter clinically in UK practice 
• Managing safe switching across secondary care, primary care and homecare 
• Identifying high-risk patients and minimising disease flare during transitions 
• Real-world evidence: are biosimilars being treated like generics? 

• Historical biosimilar switches 
• Automation via homecare 
• Governance with ‘lift & shift’ 

• Comparative evidence for paediatric biosimilars, what is currently approved and used in the UK 
• What is the difference in pharmacokinetics, dosing rages and immunogenicity in children and when is switching suitable 
• How NICE guidance applies to paediatrics biologics when biosimilars are available  
• Practicalities of switching in paediatric IBD, rheumatology and dermatology as examples

• Distinguishing true adverse events using clinical indicators and UK guidance  
• Creating a systematic approach to AE management during and after a biosimilar switch  
• Documentation, follow-up and MDT involvement: when to involve immunology, when to repeat drug-level testing and when switching back is justified 
• Developing a local exceptionality process  

• How medicines value teams approach biosimilar implementation locally 
• Working with clinicians to support confident switching 
• Monitoring uptake and outcomes beyond simple cost metrics 
• Embedding governance and documentation into routine practice 

• Key NHSE reimbursement and commissioning reforms in England 
• Practical impact of the ‘best-value biologic/biosimilar first’ agenda 
• Implications for prescribing, switching, hospital and homecare pathways